Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study

The treatment of multiple myeloma (MM) with proteasome inhibitor (PI) bortezomib has significantly improved the survival of patients with MM. The 26S proteasome inhibitor targets the unfolded protein response (UPR) by inhibiting proteasome degradation of ubiquitinated paraprotein, subsequently leadi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Qin, Xiao-Qi, An, Gang, Li, Zeng-Jun, Liu, Lan-Ting, Xu, Yan, Yang, Lin-Hua, Ma, Yan-Ping, Deng, Shu-Hui, Sui, Wei-Wei, Qin, Yu, Feng, Xiao-Yan, Zang, Mei-Rong, Yang, Wen-Juan, Zhang, Yan-Ru, Yi, Shu-Hua, Wang, Ting-Yu, Lv, Rui, Zou, De-Hui, Zhao, Yao-Zhong, Qiu, Lu-Gui
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2019
Teme:
Lymphoid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6418498/
https://ncbi.nlm.nih.gov/pubmed/30833275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019851
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki